Interleukin‑33 expression in ovarian cancer and its possible suppression of peritoneal carcinomatosis
| Autor: | Shiro Suzuki, Satomi Hattori, Yusuke Shimizu, Fumitaka Kikkawa, Yoshihiro Koya, Atsushi Sekiya, Ayako Tanaka, Hiroaki Kajiyama, Nobuhisa Yoshikawa |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
CD4-Positive T-Lymphocytes
0301 basic medicine Cancer Research medicine.medical_treatment CD8-Positive T-Lymphocytes Carcinoma Ovarian Epithelial Biology medicine.disease_cause Mice 03 medical and health sciences 0302 clinical medicine Cell Line Tumor medicine Animals Humans Peritoneal Neoplasms Ovarian Neoplasms Oncogene Cancer Interleukin Immunotherapy Interleukin-33 Prognosis medicine.disease Gene Expression Regulation Neoplastic Interleukin 33 030104 developmental biology Cytokine Oncology 030220 oncology & carcinogenesis Cancer research Female Carcinogenesis Ovarian cancer Neoplasm Transplantation |
| Zdroj: | International Journal of Oncology. |
| ISSN: | 1791-2423 1019-6439 |
| Popis: | Refractory peritoneal carcinomatosis is a common terminal feature of epithelial ovarian cancer (EOC). Previous reports have suggested that immunotherapy is a promising therapeutic strategy for EOC. Interleukin (IL)‑33 is a member of the IL‑1 superfamily of cytokines. The role of IL‑33 in tissue inflammation and promoting type 2 immune responses has been established, and recently, there is accumulating evidence to suggest the involvement of IL‑33 in carcinogenesis. In this study, we focused on the association between the tumor expression of IL‑33 and ovarian peritoneal carcinomatosis. We used an immunosufficient murine model of peritoneal carcinomatosis and human EOC samples. The overexpression of IL‑33 in the ID8 mouse EOC cell line tumors significantly prolonged the survival of immunocompetent mice in the peritoneal carcinomatosis setting, but not in the subcutaneous model. In addition, the silencing of IL‑33 in ID8‑T6 cells (subclone with high dissemination potential) significantly shortened the survival of the tumor‑bearing mice. This was likely due to the intratumoral accumulation of CD8+ and CD4+ T cells, and a decrease in CD11b+Gr1+ cells. Furthermore, IL‑33 induced the intraperitoneal microenvironment favoring tumor elimination through the inhibition of differentiation into CD11b+Gr1+ cells. On the whole, the findings of this study suggest IL‑33 to be a cytokine that reflects antitumor peritoneal conditions. Further investigation of the antitumorigenic role of IL‑33 may aid in the development of more effective therapeutic approaches for the treatment of EOC with peritoneal carcinomatosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|